Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ili-alone in advanced extremity melanoma

Annals of Surgical Oncology

Volumn 21, Issue 2, 2014, Pages 650-655

  Wong, Joyce ^a,b   Ann Chen, Y ^a   Fisher, Kate J ^a   Beasley, Georgia M ^c   Tyler, Douglas S ^c   Zager, Jonathan S ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURGERY; DEMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; ISOLATED LIMB INFUSION; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; MINIMALLY INVASIVE PROCEDURE; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; TREATMENT RESPONSE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; DACTINOMYCIN; EXTREMITIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84896721839     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3336-4     Document Type: Article

References (23)

1. American Cancer Society. Cancer facts and figures. 2012. Atlanta: American Cancer Society; 2012.
2. Melanoma of the skin. In: Edge SB, Byrd DR, Compton CC, et al., eds. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 325-44.
3. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-206.
4. Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010;28:3042-7.
5. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol. 1998;14:238-47.
6. Kroon HM, Lin DY, Kam PC, Thompson JF. Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma. Ann Surg Oncol. 2009;16:1193-201.
7. McClaine RJ, Giglia JS, Ahmad SA, et al. Quality of life outcomes after isolated limb infusion. Ann Surg Oncol. 2012;19:1372-8.
8. Barbour AP, Thomas J, Suffolk J, et al. Isolated limb infusion for malignant melanoma: predictors of response and outcome. Ann Surg Oncol. 2009;16:3463-72.
9. Alexander HR Jr, Fraker DL, Bartlett DL, et al. Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment paramenters. J Clin Oncol. 2010;28:114-8.
10. Boesch CE, Meyer T, Washcke L, et al. Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasized malignant melanoma of the extremities. Int J Hyperthermia. 2010;26:16-20.
11. Raymond AK, Beasley GM, Broadwater G, et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg. 2011;213:306-16.
12. Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008;15:2195-205.
13. Santillan AA, Zager JS. Isolated limb infusion for melanoma: a less morbid alternative to hyperthermic isolated limb perfusion in the US. Expert Opin Drug Metab Toxicol. 2010;6:1033-7.
14. Beasley GM, Sharma K, Wong J, et al. A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion. Cancer. 2012;118:6136-43.
15. Kroon HM, Moncrieff M, Kam PCA, Thompson JF. Outcomes following isolated limb infusion for melanoma: a 14-year experience. Ann Surg Oncol. 2008;15:3003-13.
16. Huismans AM, Kroon HM, Kam PCA, Thompson JF. Does increased experience with isolated limb infusion for advanced limb melanoma influence outcome? A comparision of two treatment periods at a single institution. Ann Surg Oncol. 2011;18:1877-83.
17. Beasley GM, Caudle A, Petersen RP, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg. 2009;208:106-15.
18. Santillan AA, Delman KA, Beasley GM, et al. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol. 2009;16:2570-8.
19. Sharma K, Beasley G, Turley R, et al. Patterns of recurrence following complete response to regional chemotherapy for in-transit melanoma. Ann Surg Oncol. 2012;19:2563-71.
20. Kroon HM, Lin DY, Kam PCA, Thompson JF. Major amputation for irresectable extremity melanoma after failure of isolated limb infusion. Ann Surg Oncol. 2009;16:1543-7.
21. Chai CY, Deneve JL, Beasley GM, et al. A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of the extremities. Ann Surg Oncol. 2012;19:1637-43.
22. Testori A, Intellisano A, Verrecchia F, et al. Alternatives for the treatment of local advanced disease: electrochemotherapy, limb perfusion, limb infusion, intralesional IL2. What is the role? Dermatol Ther. 2012;25:443-51.
23. Testori A, Faries MB, Thompson JF, et al. Local and intralesional therapy of in-transit melanoma metastases. J Surg Oncol. 2011;104:391-6.